The Phase 2 clinical trial was a randomized, double-blind, parallel, placebo-controlled trial in 120 subjects undergoing coronary artery bypass grafting (CABG) and/or heart valve replacement surgery requiring cardiopulmonary bypass (CPB). Patients were randomized to receive LB1148 or placebo in conjunction with surgery. The trial’s primary endpoint was time to return of bowel function with LB1148 treatment as compared to placebo. ICU length of stay, hospital length of stay, organ function changes, inflammatory response and glucose control were secondary endpoints. LB1148, provided a 30% improvement in the time to normal bowel function following cardiovascular surgery (p<0.001) compared to placebo. This improvement resulted in a 1.1-day reduction in average length of stay in the ICU and a 1.2-day reduction in average hospital length of stay. One of the primary factors in discharging patients from the hospital following surgery is the return of bowel function. Reductions in hospital stay have the potential to significantly reduce healthcare costs associated with cardiovascular surgery, as the national average for in-patient hospital expenses are estimated to be $2,500 per day. LB1148 was also shown to be safe and well-tolerated in the study.